Literature DB >> 455322

Anthracycline derivatives in new drug development programs.

M Rozencweig, C De Sloover, D D Von Hoff, H J Tagnon, F M Muggia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 455322

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

1.  Anthracycline cardiomyopathy.

Authors:  N L Kobrinsky; N K Ramsay; W Krivit
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

2.  Biosynthesis of daunorubicin glycosides: role of epsilon-rhodomycinone.

Authors:  J C McGuire; M C Thomas; R M Stroshane; B K Hamilton; R J White
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

Review 3.  m-AMSA and PALA: two new agents in cancer chemotherapy.

Authors:  M Rozencweig; D D Von Hoff; R L Cysyk; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.

Authors:  M J Oosterbaan; R J Dirks; T B Vree; E van der Kleijn
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

5.  Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

Authors:  M Bontenbal; M Andersson; J Wildiers; G Cocconi; J Jassem; R Paridaens; N Rotmensz; R Sylvester; H T Mouridsen; J G Klijn; A T van Oosterom
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.